Free LIF receptor α-chain distal cytoplasmic motifs enhance Jak2-independent STAT3 phosphorylation and induce differentiation in HL-60 cells

Oncology Reports

Volumn 26, Issue 2, 2011, Pages 399-404

  Sun, Qing ^a,b   Wang, Jing ^a   Xiong, Jun ^a   Yang, Ling ^a   Liu, Houqi ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b 401 Hospital of PLA   (China)

Author keywords

Acute promyeloid leukemia; Gp130; IL 6; Jak STAT pathway; Leukemia inhibitory factor receptor

Indexed keywords

JANUS KINASE 2; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA; STAT3 PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; UPREGULATION;

BASE SEQUENCE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYTOPLASM; HL-60 CELLS; HUMANS; JANUS KINASE 2; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA SUBUNIT; LEUKEMIA, PROMYELOCYTIC, ACUTE; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; UP-REGULATION;

EID: 79958203736     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1289     Document Type: Article

References (32)

1. Tomida M, Yamamoto-Yamaguchi Y and Hozumi M: Purification of a factor inducing differentiation of mouse myeloid leukemic M1 cells from conditioned medium of mouse fibroblast L929 cells. J Biol Chem 259: 10978-10982, 1984. (Pubitemid 14030180)
2. Gearing DP, Gough NM, King JA, et al: Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J 6: 3995-4002, 1987.
3. Zhang Y, Willson T, Metcalf D, et al: The box-1 region of the leukemia inhibitory factor receptor alpha-chain cytoplasmic domain is sufficient for hemopoietic cell proliferation and differentiation. J Biol Chem 273: 34370-34383, 1998. (Pubitemid 29008915)
4. Levy-Nissenbaum O, Sagi-Assif O, Raanani P, Avigdor A, Ben-Bassat I and Witz IP: Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Cancer Lett 199: 185-192, 2003. (Pubitemid 37297711)
5. Metcalf D: The leukemia inhibitory factor (LIF). Int J Cell Cloning 9: 95-108, 1991.
6. Hemmann U, Gerhartz C, Heesel B, et al: Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J Biol Chem 271: 12999-13007, 1996.
7. Heim MH, Kerr IM, Stark GR and Darnell JE Jr: Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 267: 1347-1349, 1995.
8. Zhang T, Seow KT, Ong CT and Cao X: Interdomain interaction of Stat3 regulates its Src homology 2 domain-mediated receptor binding activity. J Biol Chem 277: 17556-17563, 2002. (Pubitemid 34967557)
9. Liu H, Dan J, Tang S and Wu S: Involving of the cytoplasmic region of leukemia inhibitory factor receptor alpha subunit, IL-6 related signal transducer-gp130 or fes death domain for MAPK p42/44 activation in HL-60 cell with LIF or anti-Fas IgG. Mol Cell Biochem 217: 113-120, 2001.
10. White UA and Stephens JM: Neuropoietin activates STAT3 independent of LIFR activation in adipocytes. Biochem Biophys Res Commun 395: 48-50, 2010.
11. Moon DO, Kim MO, Lee JD, Choi YH and Kim GY: Butein suppresses c-Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett 286: 172-179, 2009.
12. Fang ZH, Dong CL, Chen Z, et al: Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in antileukemic strategy. J Cell Mol Med 13: 2039-2052, 2009.
13. Liu H, Liu S, Tang S, Ji K, Wang F and Hu S: Molecular analysis of signaling events mediated by the cytoplasmic domain of leukemia inhibitory factor receptor alpha subunit. Mol Cell Biochem 258: 15-23, 2004. (Pubitemid 38268196)
14. Shen ZX, Chen GQ, Ni JH, et al: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
15. Bach JP, Borta H, Ackermann W, Faust F, Borchers O and Schrader M: The secretory granule protein syncollin localizes to HL-60 cells and neutrophils. J Histochem Cytochem 54: 877-888, 2006. (Pubitemid 44106865)
16. Bromberg JF, Wrzeszczynska MH, Devgan G, et al: Stat3 as an oncogene. Cell 98: 295-303, 1999.
17. Maekawa T and Metcalf D: Clonal suppression of HL60 and U937 cells by recombinant human leukemia inhibitory factor in combination with GM-CSF or G-CSF. Leukemia 3: 270-276, 1989. (Pubitemid 19092759)
18. Meydan N, Grunberger T, Dadi H, et al: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648, 1996. (Pubitemid 26053453)
19. Giannopoulou M, Iszkula SC, Dai C, et al: Distinctive role of Stat3 and Erk-1/2 activation in mediating interferon-gamma inhibition of TGF-beta1 action. Am J Physiol Renal Physiol 290: F1234-F1240, 2006. (Pubitemid 43724924)
20. Quaglino A, Schere-Levy C, Romorini L, Meiss RP and Kordon EC: Mouse mammary tumors display Stat3 activation dependent on leukemia inhibitory factor signaling. Breast Cancer Res 9: P69, 2007.
21. Bitard J, Daburon S, Duplomb L, et al: Mutations in the immunoglobulin-like domain of gp190, the leukemia inhibitory factor (LIF) receptor, increase or decrease its affinity for LIF. J Biol Chem 278: 16253-16261, 2003. (Pubitemid 36799750)
22. Schuringa JJ, Wierenga AT, Kruijer W and Vellenga E: Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 95: 3765-3770, 2000.
23. Tomida M, Heike T and Yokota T: Cytoplasmic domains of the leukemia inhibitory factor receptor required for STAT3 activation, differentiation, and growth arrest of myeloid leukemic cells. Blood 93: 1934-1941, 1999.
24. Metcalf D, Nicola NA and Gearing DP: Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 76: 50-56, 1990. (Pubitemid 20220790)
25. Obana M, Maeda M, Takeda K, et al: Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation 121: 684-691, 2010.
26. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002. (Pubitemid 35177340)
27. Emery B, Cate HS, Marriott M, et al: Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination. Proc Natl Acad Sci USA 103: 7859-7864, 2006.
28. Nakajima K, Yamanaka Y, Nakae K, et al: A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 15: 3651-3658, 1996. (Pubitemid 26239777)
29. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021-1028, 1997. (Pubitemid 27430519)
30. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS and Huang CY: IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 289: L446-L453, 2005.
31. Levitzki A: Tyrphostins - potential antiproliferative agents and novel molecular tools. Biochem Pharmacol 40: 913-918, 1990.
32. Turkson J, Ryn D, Kim JS, et al: Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 276: 45443-45455, 2001.